April 10, 2020

Christian Bixby,
Assistant Director, Research and Clinical Lab Services, RUCDR
Rutgers Clinical Genomics Laboratory-Rutgers University
604 Allison Road,
Piscataway, NJ 08854 US

Re: EUA200090
Trade/Device Name: ThermoFisher - Applied Biosystems TaqPath COVID-19 Combo Kit
Laboratory: Rutgers Clinical Genomics Laboratory-Rutgers University
Dated: March 28, 2020
Received: March 30, 2020

Dear Christian Bixby:

This letter is in response to your request that the Food and Drug Administration (FDA) add your test as an authorized test to the March 31, 2020 Emergency Use Authorization (EUA), pursuant to Section 564 of the Federal Food, Drug, and Cosmetic Act (the Act) (21 U.S.C. §360bbb-3). We have reviewed the EUA submission package and determined that your test meets the criteria for issuance under section 564(c) of the Act because your test is eligible for authorization under the March 31, 2020 EUA for Molecular-based Laboratory Developed Tests for Detection of Nucleic Acid from SARS-CoV-2 (Molecular LDT COVID-19 Authorized Test). As such, your test is hereby added to Appendix A1 as an authorized test.

Having concluded that the criteria for issuance of this authorization under Section 564(c) of the Act are met, I am adding this test to Appendix A as an authorized test, as described in the Scope of Authorization (Section II) and pursuant to the Conditions of Authorization (Section IV) of the attached letter of authorization2 for use by the authorized laboratory to detect SARS-CoV-2 in specimens collected from individuals suspected of COVID-19 by their healthcare provider. Accordingly, in addition to this letter, you will receive copies of the FDA Letter of Authorization and the authorized Healthcare Provider and Patient Fact Sheets that must be used in conjunction with your authorized test pursuant to the Conditions of Authorization (Section IV) of the Letter of Authorization.

Sincerely yours,

____________________________
Uwe Scherf, M.Sc., Ph.D.
Director, Division of Microbiology Devices
OHT7: Office of In Vitro Diagnostics and Radiological Health
Office of Product Evaluation and Quality
Center for Devices and Radiological Health

1 Appendix A is available at, https://www.fda.gov/medical-devices/emergency-situations-medical-devices/emergency-use-authorizations.

U.S. Food & Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20903
www.fda.gov